Key statistics
Previous close$78.52
Open$77.66
Day high$79.41
Day low$77.47
52-week high$90.87
52-week low$43.18
Market cap6.52B
Volume704.13K
Average volume1.82M
P/E ratio-33.73
Forward P/E—
EPS-2.33
Dividend yield0.00%
Market context
Why it moved
PTCT edged slightly higher as continued institutional accumulation, highlighted by Principal Financial Group increasing its stake, combined with the stock's "Moderate Buy" consensus rating and a consensus price target well above current levels, supported modest upward momentum.
What is happening
Recent company-specific developments and publisher coverage.
July 17, 2026PTC Therapeutics closed essentially flat as investors digest a flurry of recent catalysts ahead of the company's Q2 2026 earnings call scheduled for July 30. Sentiment remains broadly constructive following a Q1 beat, raised full-year revenue guidance, and an upbeat outlook for Sephience — its rare disease therapy for PKU — with Bank of America Securities reiterating a Buy rating and a $95 price target this week. Mixed analyst views persist, however, as some flag regulatory uncertainties around vatiquinone for Friedreich ataxia, ongoing cash burn, and product concentration risk, while healthcare broadly drew fresh institutional attention after UBS upgraded the sector as a key allocation alongside AI themes.0.0891
July 16, 2026PTC Therapeutics closed modestly lower, edging down amid a broader healthcare sector pullback, even as analyst conviction around the stock remained strong. Bank of America Securities reiterated its Buy rating with a $95 price target today, while Cantor Fitzgerald raised its target to $130, reflecting bullish sentiment around the Sephience rare disease therapy following a strong Q1 2026 earnings beat. The company also announced Q2 2026 results will be reported July 30, a near-term catalyst investors are watching closely.-0.4059
July 15, 2026PTC Therapeutics closed up 1% on the session, though shares slipped back toward the flat line in after-hours trading, as investor focus remains on the company's strong Q1 2026 results and the promising launch of rare disease therapy Sephience. The quarter saw revenue of $273M — well above the $224M consensus — and a near-breakeven EPS of -$0.03 vs. the projected -$0.46, spurring analyst upgrades from Jefferies, TD Cowen, and BofA with price targets of $85–$93. Recent pre-planned insider sales near the $90 52-week high have drawn attention but appear routine under Rule 10b5-1 plans, with analysts pointing to Sephience's potential for over $2B in peak global sales as the core bull thesis.0.9992
July 15, 2026PTC Therapeutics shares fell sharply, pulling back roughly 14% from their recent near-52-week-high levels near $90, as a wave of insider selling and valuation concerns weighed on sentiment. Director Mary L. Smith sold ~$1.43M in shares and Chief Technical Ops Officer Neil Almstead sold ~$222K, both under pre-arranged 10b5-1 plans executed at ~$90 when the stock was trading near peak levels. While analysts at Jefferies, TD Cowen, and BofA remain bullish on Sephience's blockbuster potential and the stock beat Q1 earnings estimates handily, a Yahoo Finance analysis flagged the stock as potentially fully priced after rare disease data gains. Broader healthcare sector weakness and geopolitical-driven market volatility added further pressure.-4.0207
July 14, 2026PTC Therapeutics closed down roughly 4%, underperforming a broader healthcare sector that held relatively steady, as a risk-off session weighed on biotech names amid U.S.-Iran tensions sending oil prices surging. Adding to pressure, multiple insider transactions surfaced with a director and the Chief Technical Operations Officer both selling shares on July 9 under pre-arranged 10b5-1 plans. Investors are also weighing Royal Bank of Canada's recent price target boost to $85 (Sector Perform) against analyst consensus fair value near $93.93, with two NDAs under FDA review and a Huntington's disease Phase 3 program partnered with Novartis remaining key catalysts in focus.-4.1485
July 11, 2026PTC Therapeutics tumbled ~5% — its sharpest single-day decline in recent months — as investors locked in gains near 52-week highs, pressured by notable insider selling after the chief technical operations officer offloaded $4.1M in shares via a pre-arranged Rule 10b5-1 plan. The pullback comes despite broadly positive sentiment: Zacks upgraded PTCT to Strong Buy on July 8, analysts at Jefferies, TD Cowen, and BofA all carry Buy ratings, and Sephience's blockbuster PKU launch drove Q1 revenue to $273M — well above estimates. Shares are also extending losses ~1% in after-hours.-5.2485
July 9, 2026PTC Therapeutics closed modestly higher, touching its 52-week high of $90.86 intraday, as a Zacks upgrade to Strong Buy added to a wave of positive analyst sentiment. Multiple Wall Street firms including Jefferies, TD Cowen, and BofA have Buy ratings on the stock, citing momentum behind the Sephience launch and its potential for over $2 billion in peak global sales. The biotech sector is providing a strong tailwind, with Jim Cramer calling it 'the hottest group in the market' as M&A activity accelerates under a more favorable FDA backdrop—positioning rare-disease-focused names like PTC as potential acquisition targets.1.1065
July 9, 2026PTC Therapeutics edged lower in Tuesday's session, closing near its 52-week high, as a Zacks upgrade to Strong Buy and a raised RBC Capital price target to $85 (from $82) provided mixed sentiment — RBC maintained a cautious 'Sector Perform' rating, keeping the stock below its current price. Investor attention remains on Sephience commercial uptake and the company's raised 2026 product revenue guidance of $750–850 million, alongside a recent triple inclusion in Russell 2000 Defensive indexes that has boosted institutional visibility. Notable insider selling by executive Neil Almstead — over 50,000 shares in June — adds a counterweight to the bullish narrative.-0.7063
Simply Wall Street · July 19, 2026Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518?↗Investing.com · July 16, 2026Cantor Fitzgerald raises PTC Therapeutics stock price target on Sephience outlook↗Moomoo · July 16, 2026Cantor Fitzgerald Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Raises Target Price to $130↗Investing.com · July 15, 2026Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock↗ Benzinga · July 16, 2026Cantor Fitzgerald Maintains Overweight on PTC Therapeutics, Raises Price Target to $130Benzinga · July 7, 2026RBC Capital Maintains Sector Perform on PTC Therapeutics, Raises Price Target to $85Mt Newswire · July 7, 2026RBC Capital Adjusts PTC Therapeutics Price Target to $85 From $82, Maintains Sector Perform RatingMt Newswire · June 16, 2026PTC Therapeutics Prices $500 Million Notes OfferingMt Newswire · June 15, 2026PTC Therapeutics Plans $500 Million Convertible Notes Offering to Refinance 2026 NotesBenzinga · June 15, 2026PTC Therapeutics Announces Proposed Private Placement Of $500M Of Convertible Senior Notes Due 2031Mt Newswire · June 12, 2026PTC Therapeutics Insider Sold Shares Worth $1,595,775, According to a Recent SEC FilingMt Newswire · June 9, 2026PTC Therapeutics Shares Rise After Upgrade From Citigroup
Peers
SPXS&P 500SPX · $7,457.69-1.01%
RYTRhythm Pharmaceuticals, Inc.RYTM · $106.60+0.48%
CRSCRISPR Therapeutics AGCRSP · $47.78-1.63%
CYTCytokinetics, IncorporatedCYTK · $80.18-0.22%
BBIBridgeBio Pharma, Inc.BBIO · $81.38+1.34%
IONIonis Pharmaceuticals, Inc.IONS · $54.39-0.48%
MRNModerna, Inc.MRNA · $61.82-2.11%
SRPSarepta Therapeutics, Inc.SRPT · $17.22-0.06%
ALNAlnylam Pharmaceuticals, Inc.ALNY · $267.47-5.54%
RCKRocket Pharmaceuticals, Inc.RCKT · $3.44+0.88%
STOStoke Therapeutics, Inc.STOK · $29.05-0.21%
SNDSyndax Pharmaceuticals, Inc.SNDX · $22.80+0.40%
